Citicoline
Also sold as: CDP-choline · Cytidine diphosphocholine · Citicoline sodium
A choline-containing compound involved in phospholipid metabolism, sold for memory and attention. Clinical neurological research does not establish a universal cognitive enhancer for healthy adults.
Focus
Community
Not enough ratings yet: 0 of 10
Scores appear after 10 ratings, so that one or two reports can't dominate. Tried it? Your rating counts.
Research
- Focus: Small population-specific trials suggest memory or attention signals, but independent replication and generalization to healthy young adults remain limited.
REALITY CHECK // Brain-repair and stroke-prevention marketing outruns the clinical evidence: the large ICTUS stroke trial was negative despite earlier positive pooling. Healthy-reader evidence rests on narrow samples and selected endpoints; a branded ingredient used in one trial has not been proved universally superior to generic citicoline.
Levels: how we grade evidence. Grey = evidence of no benefit; amber = evidence it makes this goal worse.
Ratings are self-reported by a self-selected group of users: how it felt, not proof that it works.
Check your bottle
Compare what your label says with what was used in trials. This is a trial range, not a personal prescription.
Enter the amount from your label to see the result.
How it was studied
UPPER LIMIT // No established citicoline-specific EFSA/NIH UL is supplied in this dossier. Clinical exposure up to 2,000 mg/day is not an unlimited safety claim; long-term healthy-adult data are limited.
Summary
A trial in 100 adults aged 50-85 with age-associated memory complaints used 500 mg/day for 12 weeks and reported benefits on secondary memory outcomes; sponsorship and endpoint hierarchy matter. Clinical cognitive meta-analyses have substantial bias concerns. Earlier positive stroke pooling was not confirmed by the pivotal 2,298-participant ICTUS trial.
Mechanism
Oral citicoline supplies choline and cytidine-related substrates involved in phosphatidylcholine and acetylcholine synthesis. This pharmacology does not establish improved IQ, brain repair or racetam synergy.
Typical studied dose
The older-adult memory trial used 500 mg/day for 12 weeks. Clinical neurological studies described in the dossier used 500-2,000 mg/day, but acute stroke treatment is a hospital context and not an OTC nootropic regimen. These are citicoline amounts, not elemental choline targets.
Upper limit
No established citicoline-specific EFSA/NIH UL is supplied in this dossier. Clinical exposure up to 2,000 mg/day is not an unlimited safety claim; long-term healthy-adult data are limited.
Popular stacks with Citicoline
Not enough stack data yet. A combination with Citicoline appears here once 5 people rate the same set.
Forms and label traps
| Form on label | Active content | Studied range / day | Absorption & GI tolerance | Verdict |
|---|---|---|---|---|
| Citicoline sodium Best for: A clearly declared citicoline amount. |
Unstandardized: active content unknown | no comparable trial range | Absorbed after oral administration and metabolized to constituent substrates; not identical to swallowing choline alone. Generally tolerated; headache or GI symptoms may occur. |
Caution [CHECK // CAUTION] Unknown salt/base labeling prevents exact preparation matching. |
| Citicoline free form / named trial ingredient Best for: Matching the named ingredient and citicoline amount. |
Extract weight · marker not quantified | 500–500 mg | Used in the supplied older-adult memory trial; brand use is not proof of superiority. Generally tolerated in short trials. |
Studied standard [CHECK // REFERENCE] Direct citicoline mass is compared with 500 mg/day citicoline, not with its choline fraction. |
Common label traps
- TRAP_01 // REPAIRS BRAINS OR PREVENTS STROKE
ICTUS did not confirm benefit in acute ischaemic stroke; prevention in healthy readers cannot be inferred. - TRAP_02 // A MEMORY AND IQ BOOST FOR EVERYONE
Older-adult memory and adolescent male attention findings do not generalize to every healthy adult or to IQ. - TRAP_03 // MORE CHOLINE MEANS MORE FOCUS
Increasing exposure can cause unpleasant symptoms without an established dose-response benefit.
Other outcomes studied
Outside the five leaderboard goals. Same evidence levels as above.
- ACUTE ISCHAEMIC STROKE Limited · no benefit
Earlier positive pooled analyses conflict with the large negative ICTUS trial and cautious Cochrane review. This is specialist acute care, not supplement prevention.
PMID 12468781 PMID 22691567 PMID 32860632 - CLINICAL COGNITIVE IMPAIRMENT Limited · benefit
A systematic review found positive signals but poor study quality and substantial bias; disease-population results do not establish healthy-adult enhancement.
PMID 36678257 - GLAUCOMA ADJUNCT Limited · benefit
Small heterogeneous studies suggest possible functional or quality-of-life changes alongside standard ophthalmic care; they do not justify replacing pressure-lowering treatment.
PMID 37768938 PMID 36639525
Reader questions
Should I use 250, 500 or 1,000 mg?
The clearest healthy older-adult memory protocol here used 500 mg/day for 12 weeks. Higher neurological-treatment doses are not evidence that a healthy reader gains more focus.
Why does it worsen my mood?
Some users report mood deterioration or irritability, but the dossier does not establish frequency or a single mechanism. Stop and discuss significant symptoms with a clinician, especially when taking psychiatric medicines.
Is it better than Alpha-GPC?
They are different molecules. The supplied evidence does not establish a universal cognitive winner or show that combining them is beneficial.
Stack interactions
- Caution Levodopa [CAUTION // REVIEW_COMBINATION]
Possible potentiation warrants prescriber review rather than self-adjusting either product. Direct interaction citation details are absent from the supplied catalog. - Caution Alpha-GPC and other choline products [CAUTION // REVIEW_COMBINATION]
Different molecules can add choline exposure. Headache, irritability or mood changes are reasons to reassess, not evidence of a beneficial synergy. - Caution Racetams [CAUTION // REVIEW_COMBINATION]
Choline-supply rationale is mechanistic; robust clinical outcome evidence for superior racetam efficacy is not supplied.
PMID 26366063
Red flags: interactions and who should avoid it
Interactions
Citicoline may enhance levodopa effects; Parkinson care requires prescriber review. Combining it with Alpha-GPC adds choline exposure without proven outcome benefit. Mood worsening and irritability are reported signals; direct psychiatric-drug interaction trials are lacking.
Avoid or ask a doctor first if
Avoid unsupervised use in pregnancy, breastfeeding or children. Review use with Parkinson medication or a history of significant mood instability. Stop and seek assessment for substantial mood deterioration, persistent headache or GI symptoms.
Sources (PubMed, 9)
- Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial).
PMID 22691567 · 2012 · RCTPivotal negative ICTUS acute-stroke RCT.
- Oral citicoline in acute ischemic stroke: an individual patient data pooling analysis of clinical trials.
PMID 12468781 · 2002 · Systematic review / meta-analysisEarlier positive individual-patient pooling; conflicts with later pivotal evidence.
- Citicoline for treating people with acute ischemic stroke.
PMID 32860632 · 2020 · Systematic review / meta-analysisCochrane acute-stroke review.
- Is Citicoline Effective in Preventing and Slowing Down Dementia?-A Systematic Review and a Meta-Analysis.
PMID 36678257 · 2023 · Systematic review / meta-analysisCognitive-impairment review with major quality limitations.
- The Effect of Citicoline Supplementation on Motor Speed and Attention in Adolescent Males.
PMID 26179181 · 2019 · RCTAttention and motor-speed RCT in adolescent males.
- Efficacy of citicoline as a supplement in glaucoma patients: A systematic review.
PMID 37768938 · 2023 · Systematic review / meta-analysisGlaucoma systematic review.
- The effect of citicoline oral solution on quality of life in patients with glaucoma: the results of an international, multicenter, randomized, placebo-controlled cross-over trial.
PMID 36639525 · 2023 · RCTGlaucoma quality-of-life crossover trial.
- Bioavailability of methyl-14C CDP-choline by oral route.
PMID 6684463 · 1983 · Other studyOral bioavailability study.
- The role of citicoline in cognitive impairment: pharmacological characteristics, possible advantages, and doubts for an old drug with new perspectives.
PMID 26366063 · 2015 · Narrative reviewPharmacological review and uncertainties.
Community comments
No approved comments yet. Comments are held for moderation.